Biomarker Testing and Pre-emptive Therapy in Preventing Heart Failure

Ken McDonald, Mark Ledwidge, Joe Gallagher, Chris Watson

Research output: Contribution to journalArticlepeer-review


In an attempt to reduce the heart failure epidemic,screening and prevention will become an increasing focus ofmanagement in the wider at-risk population. Refining riskprediction through the use of biomarkers in isolation or incombination is emerging as a critical step in this process.The utility of biomarkers to identify disease manifestationsbefore the onset of symptoms and detrimental myocardialdamage is proving to be valuable. In addition, biomarkers thatpredict the likelihood and rate of disease progression over timewill help streamline and focus clinical efforts and therapeuticstrategies. Importantly, several recent early intervention studiesusing biomarker strategies are promising and indicate thatnot only can new-onset heart failure be reduced but also thedevelopment of other cardiovascular conditions.
Original languageEnglish
Article number27
Pages (from-to)26-31
Number of pages6
JournalCurrent Cardiovascular Risk Reports
Early online date17 Apr 2015
Publication statusPublished - May 2015


Dive into the research topics of 'Biomarker Testing and Pre-emptive Therapy in Preventing Heart Failure'. Together they form a unique fingerprint.

Cite this